Get the content you want anytime you want.

Data Presented at ASM Microbe 2017 Highlight Progress on New Antibiotics: Business Watch Report

Welcome to the first edition of the Contagion® Weekly Business Watch. As we wait to learn the fate of the Affordable Care Act (ACA) and the introduction and make-up of the American Health Care Act (AHCA), we have begun providing our readership with a Public Health Watch each week, bringing a snapshot of the latest news in public health. To this end, we feel that it is important to provide our readers with the latest information on new drugs, medical devices, and tests coming out of industry and so each week we will be publishing a Business Watch Report. In this week’s report, we include information on the latest data presented at the recent American Society for Microbiology (ASM) Microbe 2017 conference, June 1-5, 2017 in New Orleans, Louisiana.

Shionogi Presents Further Evidence on Efficacy of Cefiderocol Against MDR Gram-Negative Pathogens 

Shionogi & Co., Ltd. (Shionogi) presented results from several studies on cefiderocol (S-649266), a late-stage investigational parenteral siderophore cephalosporin at ASM Microbe 2017. Findings from epidemiological, molecular mechanism, and global surveillance studies showed that cefiderocol demonstrated potent activity against Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, and Stenotrophomonas maltophilia, including carbapenem-resistant strains of these pathogens harboring both serine and metallo-type beta-lactamases. Clinical development of cefiderocol for the U.S. is ongoing with a phase 3 trial in patients with carbapenem-resistant pathogens at various infection sites (CREDIBLE-CR). Also scheduled to start in 2017 is a phase 3 trial in patients with hospital-acquired/ventilator-associated/healthcare-associated pneumonia HAP/VAP/HCAP† (APEKS*-NP‡). Shionogi plans to submit a new drug application (NDA) to the FDA in 2017 with data from a recently completed registrational study in patients with cUTI (APEKS*-cUTI).
ASM Microbe 2017 Presentations:

Nabriva Therapeutics Showcases Data on Pleuromutilin Class of Antibiotics 

Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, presented data at ASM Microbe 2017 last weekend. The company showcased 4 poster presentations on lefamulin’s in vitro activity against key pathogens commonly causing respiratory tract infections. These data are part of a growing body of evidence supporting lefamulin’s profile as a potential first-line, empiric treatment for the key pathogens, including multidrug resistant strains, that are known to cause community-acquired bacterial pneumonia (CABP).  The data presented at ASM Microbe 2017 are supportive of Nabriva's ongoing Phase 3 clinical development program and the company will report top-line results from its first pivotal trial, known as LEAP 1, in the third quarter of 2017.
ASM Microbe 2017 Presentations:   

Big advances in treatment can